Table 2.

Associations of left ventricular mass index quartiles with incident heart failure in the Chronic Renal Insufficiency Cohort participants without heart failure

LVMI Q (g/m2.7)N (Events)N (Participants)Rate (Events/1000 person-yr)HR (95% CI)
Model 1Model 2Model 3
All
 Q1 (<41.3)116412.8ReferenceReferenceReference
 Q2 (41.3 to <48.5)296438.01.82 (0.9 to 3.7)1.73 (0.85 to 3.52)1.55 (0.76 to 3.17)
 Q3 (48.5 to <57.5)5564216.73.19 (1.62 to 6.3)3.05 (1.54 to 6.04)2.71 (1.36 to 5.4)
 Q4 (≥57.5)11964143.25.23 (2.63 to 10.41)4.89 (2.45 to 9.75)3.96 (1.96 to 8.02)
 Linear trend P value<0.001<0.001<0.001
Men
 Q1 (<41.7)53452.4ReferenceReferenceReference
 Q2 (41.7 to <48.8)173449.12.25 (0.81 to 6.23)2.21 (0.8 to 6.14)1.89 (0.67 to 5.32)
 Q3 (48.8 to <57.4)3334519.23.77 (1.42 to 10.01)3.57 (1.34 to 9.49)3.06 (1.14 to 8.23)
 Q4 (≥57.4)5934442.24.61 (1.7 to 12.5)4.38 (1.61 to 11.89)3.52 (1.28 to 9.71)
 Linear trend P value<0.01<0.010.05
Women
 Q1 (<40.8)62973.3ReferenceReferenceReference
 Q2 (40.8 to <47.9)122976.91.43 (0.52 to 3.9)1.23 (0.45 to 3.39)1.2 (0.43 to 3.35)
 Q3 (47.9 to <57.7)2329814.62.91 (1.11 to 7.65)2.8 (1.06 to 7.41)2.64 (0.97 to 7.19)
 Q4 (≥57.7)5929743.76.41 (2.41 to 17.04)5.27 (1.97 to 14.12)4.96 (1.78 to 13.81)
 Linear trend P value<0.001<0.001<0.001
  • Model 1: age, race, study site, diabetes, cardiovascular disease, tobacco, alcohol use, log(24-hour proteinuria), eGFR (Chronic Renal Insufficiency Cohort equation), systolic BP, diastolic BP, body mass index, LDL, HDL, aldosterone antagonists, angiotensin–converting enzyme inhibitors, angiotensin receptor blockers, diuretics, β-blockers, phosphate, and hemoglobin. Model 2: model 1 plus log(parathyroid hormone), log(fibroblast growth factor-23), aspirin, and statin. Model 3: model 2 plus log(B–type natriuretic peptide) and log(high–sensitivity troponin T). LVMI, left ventricular mass index; Q, quartile; HR, hazard ratio; 95% CI, 95% confidence interval.